[REVISION HISTORY]

AIFA pharmaceutical innovation and evaluation discussions

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-10-23 12:26 UTC → 2026-10-23 12:35 UTC · added ~~removed~~

The Italian Medicines Agency (AIFA) has initiated institutional dialogues focused on the value of pharmaceutical innovation and its impact on the Italian National Health Service. During a conference in Genoa, discussions centered on developing advanced models to evaluate drug innovation, emphasizing that assessments should look beyond clinical efficacy to include patient outcomes and the economic sustainability of healthcare systems. AIFA President Robert Nisticò has further ~~expanded on~~ detailed these ~~themes by highlighting~~ themes, noting that scientific research is shifting focus from merely treating symptoms to addressing underlying biological processes. He highlighted advancements in ~~personalized and intelligent~~ targeted therapies, ~~such as~~ including gene ~~therapy and~~ therapy, genomic editing, and CAR-T cell therapies, which ~~target underlying biological processes rather than just symptoms.~~ engineer a patient’s own lymphocytes to attack tumor cells. These sophisticated treatments aim to improve both disease progression and patient quality of life. Regarding the regulatory framework, Nisticò ~~noted~~ explained that ~~while~~ drug authorization begins at the European level through the European Medicines Agency (EMA) ~~handles centralized authorization through~~ based on a benefit-risk ~~assessments,~~ assessment. Following EMA approval, individual member ~~states~~ states, such as Italy, remain responsible for ~~evaluating~~ conducting further evaluations regarding the sustainability of these new medicines within their respective national health frameworks.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.